PMID- 33235436
OWN - NLM
STAT- MEDLINE
DCOM- 20210823
LR  - 20220418
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 14
DP  - 2020
TI  - Chrysophanol Inhibits the Progression of Diabetic Nephropathy via Inactivation of 
      TGF-beta Pathway.
PG  - 4951-4962
LID - 10.2147/DDDT.S274191 [doi]
AB  - BACKGROUND: Diabetic nephropathy (DN) is a common form of diabetic complication 
      which threatens the health of patients with diabetes. It has been reported that 
      chrysophanol (CHR) can alleviate the progression of diabetes; however, the role 
      of CHR in DN remains unclear. METHODS: To mimic DN in vitro, human podocytes 
      (AB8/13 cells) were treated with high glucose (HG). Meanwhile, Western blot was 
      performed to detect protein expressions. CCK-8 assay was used to test cell 
      viability and cell proliferation was detected by Ki-67 staining. In addition, 
      flow cytometry was performed to investigate cell apoptosis and cycle and cell 
      migration was tested by transwell assay. Moreover, in vivo model of DN was 
      established to detect the effect of CHR on DN in vivo. RESULTS: HG-induced AB8/13 
      cell growth inhibition was significantly rescued by CHR. In addition, HG notably 
      promoted the migration of AB8/13 cells, while this phenomenon was obviously 
      reversed by CHR. Moreover, CHR inhibited the progression of DN via inactivation 
      of TGF-beta/EMT axis. Furthermore, CHR alleviated the symptom of DN in vivo. 
      CONCLUSION: CHR significantly alleviated the progression of DN via inactivation 
      of TGF-beta/EMT signaling in vitro and in vivo. Our findings were helpful to uncover 
      the mechanism by which CHR regulates DN, as well as inspire the development of 
      novel therapy against DN.
CI  - (c) 2020 Guo et al.
FAU - Guo, Chuan
AU  - Guo C
AD  - Department of Traditional Chinese Medicine, Peking Union Medical College 
      Hospital, Peking Union Medical College, Chinese Academy of Medical Science, 
      Beijing 100730, People's Republic of China.
AD  - Department of Nephropathy, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing 100053, People's Republic of China.
FAU - Wang, Yarong
AU  - Wang Y
AD  - Department of Traditional Chinese Medicine, Peking Union Medical College 
      Hospital, Peking Union Medical College, Chinese Academy of Medical Science, 
      Beijing 100730, People's Republic of China.
FAU - Piao, Yuanlin
AU  - Piao Y
AD  - Department of Traditional Chinese Medicine, Peking Union Medical College 
      Hospital, Peking Union Medical College, Chinese Academy of Medical Science, 
      Beijing 100730, People's Republic of China.
FAU - Rao, Xiangrong
AU  - Rao X
AD  - Department of Nephropathy, Guang'anmen Hospital, China Academy of Chinese Medical 
      Sciences, Beijing 100053, People's Republic of China.
FAU - Yin, Dehai
AU  - Yin D
AD  - Department of Traditional Chinese Medicine, Peking Union Medical College 
      Hospital, Peking Union Medical College, Chinese Academy of Medical Science, 
      Beijing 100730, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20201116
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Anthraquinones)
RN  - 0 (Transforming Growth Factor beta)
RN  - 5W494URQ81 (Streptozocin)
RN  - N1ST8V8RR2 (chrysophanic acid)
SB  - IM
MH  - Animals
MH  - Anthraquinones/*pharmacology
MH  - Apoptosis/drug effects
MH  - Cell Cycle/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cells, Cultured
MH  - Diabetic Nephropathies/*drug therapy/metabolism/pathology
MH  - Disease Models, Animal
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Streptozocin
MH  - Transforming Growth Factor beta/*antagonists & inhibitors/metabolism
PMC - PMC7678702
OTO - NOTNLM
OT  - EMT
OT  - TGF-beta
OT  - chrysophanol
OT  - diabetic nephropathy
COIS- The authors declared no competing interests in this research.
EDAT- 2020/11/26 06:00
MHDA- 2021/08/24 06:00
PMCR- 2020/11/16
CRDT- 2020/11/25 05:45
PHST- 2020/07/27 00:00 [received]
PHST- 2020/10/18 00:00 [accepted]
PHST- 2020/11/25 05:45 [entrez]
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2021/08/24 06:00 [medline]
PHST- 2020/11/16 00:00 [pmc-release]
AID - 274191 [pii]
AID - 10.2147/DDDT.S274191 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2020 Nov 16;14:4951-4962. doi: 10.2147/DDDT.S274191. 
      eCollection 2020.